Two years after the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s Invokana, the FDA issued a drug safety communication that warned doctors and patients that Invokana may lead to diabetic ketoacidosis (DKA).
Invokana is a new class of Type 2 diabetes drug called sodium-glucose co-transporter 2 (SGLT2). This class of Type 2 diabetes drugs work by stopping glucose from being reabsorbed into the blood. The FDA approved Invokana in 2013. In May 2015 the FDA release a statement warning doctors and patients that SGLT2 drugs may lead to DKA. If DKA is left untreated, it can be fatal.
In December 2015, the FDA ordered manufacturers of SGLT2 inhibitors to add warnings regarding the risk of urinary tract infection and ketoacidosis to the drugs’ labels.
Dallas Fort Worth Injury Lawyer Blog


According to a lawsuit filed by Ami Dodson, the drug caused her to suffer from permanent hair loss. Dodson’s lawsuit also alleges that the makers of Taxotere engaged in marketing schemes to drive up the sales of the drug while hiding the medication’s increased toxicity compared to other similar drugs.
Five products produced by C.R. Bard and Cook Medical are at the center of these lawsuits. These products include: